A randomized comparison of nativeEscherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia: a Children's Cancer Group study
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
For this study, 118 children with standard-risk acute lymphoblastic leukemia (ALL) were given randomized assignments to receive native or pegylated Escherichia coli asparaginase as part of induction and 2 delayed intensification phases. Patients treated with pegaspargase had more rapid clearance of lymphoblasts from day 7 and day 14 bone marrow aspirates and more prolonged asparaginase activity than those treated with native asparaginase. In the first delayed intensification phase, 26% of native asparaginase patients had high-titer antibodies, whereas 2% of pegaspargase patients had those levels. High-titer antibodies were associated with low asparaginase activity in the native arm, but not in the pegaspargase arm. Adverse events, infections, and hospitalization were similar between arms. Event-free survival at 3 years was 82%. A population pharmacodynamic model using the nonlinear mixed effects model (NONMEM) program was developed that closely fit the measured enzyme activity and asparagine concentrations. Half-lives of asparaginase were 5.5 days and 26 hours for pegaspargase and native asparaginase, respectively. There was correlation between asparaginase enzymatic activity and depletion of asparagine or glutamine in serum. In cerebrospinal fluid asparagine, depletion was similar with both enzyme preparations. Intensive pegaspargase for newly diagnosed ALL should be tested further in a larger population.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1977) · British Journal of Cancer · doi:10.1038/bjc.1977.1 · Cited by 8,285
Nonparametric Statistical Methods
(1999) · Technometrics · doi:10.1080/00401706.1999.10485954 · Cited by 6,090
Nonparametric Statistical Methods.
Knott, M., Hollander, M., & Wolfe, D. A. (1974) · Journal of the Royal Statistical Society. Series A (General) · doi:10.2307/2344557 · Cited by 2,662
Nonparametric Statistical Methods
Gibbons, J. D. (1974) · Technometrics · doi:10.1080/00401706.1974.10489221 · Cited by 1,115
Pui, C.-H. (1995) · New England Journal of Medicine · doi:10.1056/nejm199506153322407 · Cited by 379
Comparative pharmacokinetic studies of three asparaginase preparations.
Asselin, B. L., Whitin, J. C., Coppola, D. J., Rupp, I. P., Sallan, S. E., & Cohen, H. J. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.9.1780 · Cited by 333
Toxicity of E. coli L-asparaginase in man
Oettgen, H. F., Stephenson, P. A., Schwartz, M. K., Leeper, R. D., Tallal, L., Tan, C. C., Clarkson, B. D., Golbey, R. B., Krakoff, I. H., Karnofsky, D. A., et al. (1970) · Cancer · doi:10.1002/1097-0142(197002)25:2<253::aid-cncr2820250204>3.0.co;2-u · Cited by 290
Abuchowski, A., Kazo, G. M., Cr, V., Es, T. V., Kafkewitz, D., Ml, N., At, V., & Ff, D. (1984) · PubMed · Cited by 249
Tubergen, D. G., Gilchrist, G. S., O'Brien, R. T., Coccia, P. F., Sather, H. N., Waskerwitz, M. J., & Hammond, G. D. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.3.527 · Cited by 221
Self-citationSallan, S. E., Hitchcock‐Bryan, S., Gelber, R. D., Cassady, J. R., Frei, E., & Nathan, D. (1983) · PubMed · Cited by 220
Boos, J., Werber, G., Ahlke, E., Schulze-Westhoff, P., Nowak-Göttl, U., Würthwein, G., Verspohl, E. J., Ritter, J., & Jürgens, H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00131-1 · Cited by 218
L-Asparaginase and PEG Asparaginase— Past, Present, and Future
Keating, M. J., Holmes, R., Lerner, S., & Ho, D. H. (1993) · Leukemia & Lymphoma · doi:10.3109/10428199309149129 · Cited by 217
Woo, M. H., Hak, L. J., Storm, M. C., Sandlund, J. T., Ribeiro, R. C., Rivera, G. K., Rubnitz, J. E., Harrison, P. L., Wang, B., Evans, W. E., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.7.1525 · Cited by 182
Abshire, T. C., Pollock, B. H., Billett, A. L., Bradley, P., & Buchanan, G. R. (2000) · Blood · doi:10.1182/blood.v96.5.1709 · Cited by 152
Woo, M., Hak, L., Storm, M., Evans, W., Sandlund, J. T., Rivera, G. K., Wang, B., Pui, C., & Relling, M. V. (1998) · Leukemia · doi:10.1038/sj.leu.2401162 · Cited by 128
Nachman, J. B., Sather, H. N., Cherlow, J. M., Sensel, M. G., Gaynon, P. S., Lukens, J. N., Wolff, L. J., & Trigg, M. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.3.920 · Cited by 125
Self-citationMüller, H., Löning, L., Horn, A., Schwabe, D., Gunkel, M., Schrappe, M., Von Schütz, V., Henze, G., Casimiro da Palma, J., Ritter, J., et al. (2000) · British Journal of Haematology · doi:10.1046/j.1365-2141.2000.02187.x · Cited by 120
Clinical pharmacology of polyethylene glycol-L-asparaginase.
Ho, D. H., Brown, N. S., Yen, A., Holmes, R., Keating, M. J., Abuchowski, A., Newman, R. A., & Krakoff, I. H. (1986) · Drug Metabolism and Disposition · doi:10.1016/s0090-9556(25)08348-5 · Cited by 119
Ahlke, E., ̈TTL, U. N., Schulze-Westhoff, P., WERBER, G., ̈RSTE, H. B., Würthwein, G., ̈RGENS, H. J., & Boos, J. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.d01-2089.x · Cited by 117
Immunological responses to l-asparaginase
Peterson, R. G., Handschumacher, R. E., & Mitchell, M. S. (1971) · Journal of Clinical Investigation · doi:10.1172/jci106579 · Cited by 94
Pharmacology of Escherichia coli-L-asparaginase polyethylene glycol adduct.
Park, Y. K., Abuchowski, A., Davis, S., & Davis, F. (1981) · PubMed · Cited by 87
Holcenberg, J. S., & Roberts, J. (1977) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pa.17.040177.000525 · Cited by 85
Self-citationCheung, N. V., Chau, I. Y., & Coccia, P. F. (1986) · PubMed · Cited by 71
Cited by
Pui, C.-H., Robison, L. L., & Look, A. T. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60457-2 · Cited by 1,564
L‐asparaginase treatment in acute lymphoblastic leukemia: A focus on Erwinia asparaginase
Pieters, R., Hunger, S. P., Boos, J., Rizzari, C., Silverman, L., Baruchel, A., Goekbuget, N., Schrappe, M., & Pui, C. (2011) · Cancer · doi:10.1002/cncr.25489 · Cited by 569
Vora, A., Goulden, N., Wade, R., Mitchell, C., Hancock, J., Hough, R., Rowntree, C., & Richards, S. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70600-9 · Cited by 478
Schultz, K. R., Pullen, D. J., Sather, H. N., Shuster, J. J., Devidas, M., Borowitz, M. J., Carroll, A. J., Heerema, N. A., Rubnitz, J. E., Loh, M. L., et al. (2007) · Blood · doi:10.1182/blood-2006-01-024729 · Cited by 475
Self-citationBiodistribution, Clearance, and Long‐Term Fate of Clinically Relevant Nanomaterials
Bourquin, J., Milosevic, A., Hauser, D., Lehner, R., Blank, F., Petri‐Fink, A., & Rothen‐Rutishauser, B. (2018) · Advanced Materials · doi:10.1002/adma.201704307 · Cited by 461
Metadata
- Authors
- Avramis, V. I., Sencer, S., Periclou, A. P., Sather, H., Bostrom, B. C., Cohen, L. J., Ettinger, A. G., Ettinger, L. J., Franklin, J., Gaynon, P. S., Hilden, J. M., Lange, B., Majlessipour, F., Mathew, P., Needle, M., Neglia, J., Reaman, G., & Holcenberg, J. S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2002-03-15
- Volume
- 99
- Issue
- 6
- Pages
- 1986-1994
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2117623554
- Cited by
- 492
- References
- 25
- FWCI
- 9.33
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.